Amylyx Pharmaceuticals, Inc. (AMLX) Cash and securities
- Total cash · latest quarter (USD): Value $250.76M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $250.76M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $49.33M + $201.43M ≈ $250.76M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 49.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 201.43M USD | Marketable Securities, Current |
| Cash and current securities | 250.76M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $250.76M | (m) | $49.33M | $201.43M | (m) |
| 2026-03-31 | $279.77M | (m) | $229.14M | $50.63M | (m) |
| 2025-12-31 | $316.98M | (m) | $226.65M | $90.33M | (m) |
| 2025-09-30 | $343.99M | (m) | $225.18M | $118.81M | (m) |
| 2025-06-30 | $180.83M | (m) | $58.09M | $122.74M | (m) |
| 2025-03-31 | $204.07M | (m) | $59.76M | $144.30M | (m) |
| 2024-12-31 | $176.50M | (m) | $77.39M | $99.11M | (m) |
| 2024-09-30 | $234.40M | (m) | $71.84M | $162.56M | (m) |
| 2024-06-30 | (m) | (m) | $75.00M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $170.55M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $170.20M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $135.26M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $247.76M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $114.56M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $62.53M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $107.73M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $67.44M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $110.40M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $50.19M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |